Skip to main content
×
Login
Submit a Manuscript
Home
Journal
Current Issue
Archive
For Authors
Column Series
Research & Insight
Special Reports
Subscribe
Resources
Blogs
Expert Insights
Latest News
Pathways Beyond Oncology
Topics
Comparative Effectiveness Research
Cost-Effectiveness Research
COVID-19 Updates
Guideline Updates
Health Economics and Outcomes Research
Health Technology
Real-World Data
Reimbursement
Value-Based Care
Specialties
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
B-Cell Lymphoma
Biosimilars
Bladder Cancer
Breast Cancer
CAR-T Therapies
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Colorectal Cancer
Diffuse Large B-Cell Lymphoma
Esophageal Cancer
Follicular Lymphoma
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Immuno-Oncology
Kidney Cancer
Liver Cancer
Lung Cancer
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Non-Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Skin Cancer
Supportive Care
Excellence Forums
Mantle Cell Lymphoma Excellence Forum
Prostate Cancer Excellence Forum
Conferences
Oncology Clinical Pathways Congress
ASCO Gastrointestinal Cancers Symposium
ASCO Genitourinary Cancers Symposium
SGO Annual Meeting on Women's Cancer
NCCN Annual Conference
Oncology CME
About
About Us
Contact
Biosimilars Excellence Forum
Leukemia & Lymphoma
News
Real-World Safety Results of Biosimilar Administration for DLBCL
June 18, 2019
Published data presented at the ASCO Annual Meeting highlighted the post-approval safety of a biosimilar product for DLBCL.
News
Biosimilar Proves Safe, Effective in Patients With DLBCL
February 16, 2018
A recent study found that a biosimilar provides improved outcomes without increased risk of toxicity for patients with DLBCL and treatment-induced neutropenia.
Stay in the know.
Journal of Clinical Pathways Newsletter
Back to Top